Downstaging strategies for unresectable hepatocellular carcinoma

doi:10.3748/wjg.v30.i20.2731

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 20

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1929)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

1586

Sum=1631

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

148

Sum=202

May 28, 2024 (publication date) through Jan 13, 2025

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastroenterol. May 28, 2024; 30(20): 2731-2733
Published online May 28, 2024. doi: 10.3748/wjg.v30.i20.2731

Downstaging strategies for unresectable hepatocellular carcinoma

Georgia Sofia Karachaliou, Nikolaos Dimitrokallis, Dimitrios P Moris

Georgia Sofia Karachaliou, Division of Gastroenterology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States

Nikolaos Dimitrokallis, First Department of Surgery & Organ Transplant Unit, Evangelismos General Hospital, Athens 10676, Greece

Dimitrios P Moris, Department of Surgery, Duke University Medical Center, Durham, NC 27710, United States

Author contributions: Karachaliou GS and Moris DP designed the research study; Dimitrokallis N and Moris DP performed the research; Karachaliou GS and Moris DP analyzed the data and wrote the manuscript; and all authors have read and approve the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Dimitrios P Moris, MD, MSc, PhD, Surgeon, Department of Surgery, Duke University Medical Center, 2301 Erwin Road, Durham, NC 27710, United States. dimmoris@yahoo.com

Received: January 26, 2024
Revised: April 7, 2024
Accepted: April 30, 2024
Published online: May 28, 2024
Processing time: 121 Days and 16.3 Hours

Core Tip

Core Tip: Patients with hepatocellular carcinoma who undergo successful conversion therapy followed by curative-intent surgery may achieve a significant survival benefit compared to those who receive chemotherapy only without surgery. Hepatic artery infusion chemotherapy can be a potential downstaging strategy, since recent studies have demonstrated excellent outcomes in patients with colorectal liver metastatic disease as well as primary liver malignancies.